Repotrectinib Shows Durable Response in NTRK Fusion–Positive Advanced Solid Tumors – TRIDENT-1 Trial
Repotrectinib: A New Hope for Rare NTRK Fusion Cancers The fight against cancer is constantly evolving, and a recent breakthrough published in Nature Medicine offers significant hope for patients battling rare cancers driven by NTRK gene fusions. The TRIDENT-1 trial, a phase 1/2 study, demonstrates the safety and remarkable effectiveness of repotrectinib, a new tyrosine … Read more